Restricted accessResearch articleFirst published online 2018-11
Seamless Genetic Conversion of SMN2 to SMN1 via CRISPR/Cpf1 and Single-Stranded Oligodeoxynucleotides in Spinal Muscular Atrophy Patient-Specific Induced Pluripotent Stem Cells
Spinal muscular atrophy (SMA) is a kind of neuromuscular disease characterized by progressive motor neuron loss in the spinal cord. It is caused by mutations in the survival motor neuron 1 (SMN1) gene. SMN1 has a paralogous gene, survival motor neuron 2 (SMN2), in humans that is present in almost all SMA patients. The generation and genetic correction of SMA patient-specific induced pluripotent stem cells (iPSCs) is a viable, autologous therapeutic strategy for the disease. Here, c-Myc-free and non-integrating iPSCs were generated from the urine cells of an SMA patient using an episomal iPSC reprogramming vector, and a unique crRNA was designed that does not have similar sequences (≤3 mismatches) anywhere in the human reference genome. In situ gene conversion of the SMN2 gene to an SMN1-like gene in SMA-iPSCs was achieved using CRISPR/Cpf1 and single-stranded oligodeoxynucleotide with a high efficiency of 4/36. Seamlessly gene-converted iPSC lines contained no exogenous sequences and retained a normal karyotype. Significantly, the SMN expression and gems localization were rescued in the gene-converted iPSCs and their derived motor neurons. This is the first report of an efficient gene conversion mediated by Cpf1 homology-directed repair in human cells and may provide a universal gene therapeutic approach for most SMA patients.
Get full access to this article
View all access options for this article.
References
1.
OginoS, LeonardDG, RennertH, et al.Genetic risk assessment in carrier testing for spinal muscular atrophy. Am J Med Genet, 2002; 110:301–307.
2.
PriorTW. Spinal muscular atrophy: a time for screening. Curr Opin Pediatr, 2010; 22:696–702.
3.
AliasL, BernalS, Fuentes-PriorP, et al.Mutation update of spinal muscular atrophy in Spain: molecular characterization of 745 unrelated patients and identification of four novel mutations in the SMN1 gene. Hum Genet, 2009; 125:29–39.
4.
LorsonCL, HahnenE, AndrophyEJ, et al.A single nucleotide in the SMN gene regulates splicing and is responsible for spinal muscular atrophy. Proc Natl Acad Sci U S A, 1999; 96:6307–6311.
5.
ElsheikhB, PriorT, ZhangX, et al.An analysis of disease severity based on SMN2 copy number in adults with spinal muscular atrophy. Muscle Nerve, 2009; 40:652–656.
6.
CherryJJ, KobayashiDT, LynesMM, et al.Assays for the identification and prioritization of drug candidates for spinal muscular atrophy. Assay Drug Dev Technol, 2014; 12:315–341.
7.
OsmanEY, YenPF, LorsonCL. Bifunctional RNAs targeting the intronic splicing silencer N1 increase SMN levels and reduce disease severity in an animal model of spinal muscular atrophy. Mol Ther, 2012; 20:119–126.
8.
KeilJM, SeoJ, HowellMD, et al.A short antisense oligonucleotide ameliorates symptoms of severe mouse models of spinal muscular atrophy. Mol Ther Nucl acids, 2014; 3:e174.
9.
HammondSM, HazellG, ShabanpoorF, et al.Systemic peptide-mediated oligonucleotide therapy improves long-term survival in spinal muscular atrophy. Proc Natl Acad Sci U S A, 2016; 113:10962–10967.
10.
d'YdewalleC, RamosDM, PylesNJ, et al.The antisense transcript SMN-AS1 regulates SMN expression and is a novel therapeutic target for spinal muscular atrophy. Neuron, 2017; 93:66–79.
11.
FinkelRS, MercuriE, DarrasBT, et al.Nusinersen versus sham control in infantile-onset spinal muscular atrophy. New Engl J Med, 2017; 377:1723–1732.
12.
DiMatteoD, CallahanS, KmiecEB. Genetic conversion of an SMN2 gene to SMN1: a novel approach to the treatment of spinal muscular atrophy. Exp Cell Res, 2008; 314:878–886.
13.
CortiS, NizzardoM, SimoneC, et al.Genetic correction of human induced pluripotent stem cells from patients with spinal muscular atrophy. Sci Transl Med, 2012; 4:165ra162.
14.
MaliP, YangL, EsveltKM, et al.RNA-guided human genome engineering via Cas9. Science, 2013; 339:823–826.
15.
WhitworthKM, BenneJA, SpateLD, et al.Zygote injection of CRISPR/Cas9 RNA successfully modifies the target gene without delaying blastocyst development or altering the sex ratio in pigs. Transgen Res, 2017; 26:97–107.
16.
RichardsonCD, RayGJ, BrayNL, et al.Non-homologous DNA increases gene disruption efficiency by altering DNA repair outcomes. Nat Commun, 2016; 7:12463.
17.
ParkCY, KimDH, SonJS, et al.Functional correction of large factor VIII gene chromosomal inversions in hemophilia A patient-derived iPSCs using CRISPR-Cas9. Cell Stem Cell, 2015; 17:213–220.
18.
TangZH, ChenJR, ZhengJ, et al.Genetic correction of induced pluripotent stem cells from a deaf patient with MYO7A mutation results in morphologic and functional recovery of the derived hair cell-like cells. Stem Cells Transl Med, 2016; 5:561–571.
19.
NiuX, HeW, SongB, et al.Combining single strand oligodeoxynucleotides and CRISPR/Cas9 to correct gene mutations in beta-thalassemia-induced pluripotent stem cells. J Biol Chem, 2016; 291:16576–16585.
20.
ZetscheB, GootenbergJS, AbudayyehOO, et al.Cpf1 is a single RNA-guided endonuclease of a class 2 CRISPR-Cas system. Cell, 2015; 163:759–771.
21.
KimD, KimJ, HurJK, et al.Genome-wide analysis reveals specificities of Cpf1 endonucleases in human cells. Nat Biotechnol, 2016; 34:863–868.
22.
KleinstiverBP, TsaiSQ, PrewMS, et al.Genome-wide specificities of CRISPR-Cas Cpf1 nucleases in human cells. Nat Biotechnol, 2016; 34:869–874.
23.
TothE, WeinhardtN, BencsuraP, et al.Cpf1 nucleases demonstrate robust activity to induce DNA modification by exploiting homology directed repair pathways in mammalian cells. Biol Direct, 2016; 11:46.
24.
ZhangY, LongC, LiH, et al.CRISPR-Cpf1 correction of muscular dystrophy mutations in human cardiomyocytes and mice. Sci Adv, 2017; 3:e1602814.
25.
DuZW, ChenH, LiuH, et al.Generation and expansion of highly pure motor neuron progenitors from human pluripotent stem cells. Nat Commun, 2015; 6:6626.
26.
SunY, GeY, DrnevichJ, et al.Mammalian target of rapamycin regulates miRNA-1 and follistatin in skeletal myogenesis. J Cell Biol, 2010; 189:1157–1169.
27.
WooCJ, MaierVK, DaveyR, et al.Gene activation of SMN by selective disruption of lncRNA-mediated recruitment of PRC2 for the treatment of spinal muscular atrophy. Proc Natl Acad Sci U S A, 2017; 114:E1509–E1518.
28.
AndreassiC, AngelozziC, TizianoFD, et al.Phenylbutyrate increases SMN expression in vitro: relevance for treatment of spinal muscular atrophy. Eur J Hum Genet, 2004; 12:59–65.
29.
XueY, CaiX, WangL, et al.Generating a non-integrating human induced pluripotent stem cell bank from urine-derived cells. PloS One, 2013; 8:e70573.
LiuH, LuJ, ChenH, et al.Spinal muscular atrophy patient-derived motor neurons exhibit hyperexcitability. Sci Rep, 2015; 5:12189.
32.
WeiX, TanH, YangP, et al.Notable carrier risks for individuals having two copies of SMN1 in spinal muscular atrophy families with 2-copy alleles: estimation based on Chinese meta-analysis data. J Genet Counsel, 2017; 26:72–78.
PangJ, WuY, LiZ, et al.Targeting of the human F8 at the multicopy rDNA locus in hemophilia A patient-derived iPSCs using TALENickases. Biochem Biophys Res Commun, 2016; 472:144–149.
35.
WuY, HuZ, LiZ, et al.In situ genetic correction of F8 intron 22 inversion in hemophilia A patient-specific iPSCs. Sci Rep, 2016; 6:18865.
36.
ZouJ, MaliP, HuangX, et al.Site-specific gene correction of a point mutation in human iPS cells derived from an adult patient with sickle cell disease. Blood, 2011; 118:4599–4608.
37.
YangH, WangH, ShivalilaCS, et al.One-step generation of mice carrying reporter and conditional alleles by CRISPR/Cas-mediated genome engineering. Cell, 2013; 154:1370–1379.
38.
BrichtaL, HofmannY, HahnenE, et al.Valproic acid increases the SMN2 protein level: a well-known drug as a potential therapy for spinal muscular atrophy. Hum Mol Genet, 2003; 12:2481–2489.
39.
PassiniMA, BuJ, RichardsAM, et al.Antisense oligonucleotides delivered to the mouse CNS ameliorate symptoms of severe spinal muscular atrophy. Sci Transl Med, 2011; 3:72ra18.
40.
ChenPC, GaisinaIN, El-KhodorBF, et al.Identification of a maleimide-based glycogen synthase kinase-3 (GSK-3) inhibitor, BIP-135, that prolongs the median survival time of Delta7 SMA KO mouse model of spinal muscular atrophy. ACS Chem Neurosci, 2012; 3:5–11.
41.
Benkhelifa-ZiyyatS, BesseA, RodaM, et al.Intramuscular scAAV9-SMN injection mediates widespread gene delivery to the spinal cord and decreases disease severity in SMA mice. Mol Ther, 2013; 21:282–290.
42.
AzzouzM, LeT, RalphGS, et al.Lentivector-mediated SMN replacement in a mouse model of spinal muscular atrophy. J Clin Invest, 2004; 114:1726–1731.
43.
MendellJR, Al-ZaidyS, ShellR, et al.Single-dose gene-replacement therapy for spinal muscular atrophy. New Engl J Med, 2017; 377:1713–1722.
44.
RashnonejadA, GunduzC, SusluerSY, et al.In vitro gene manipulation of spinal muscular atrophy fibroblast cell line using gene-targeting fragment for restoration of SMN protein expression. Gene Ther, 2016; 23:10–17.
45.
FeldkotterM, SchwarzerV, WirthR, et al.Quantitative analyses of SMN1 and SMN2 based on real-time lightCycler PCR: fast and highly reliable carrier testing and prediction of severity of spinal muscular atrophy. Am J Hum Genet, 2002; 70:358–368.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
